Fosmidomycin uptake into Plasmodium and Babesia-infected erythrocytes is facilitated by parasite-induced new permeability pathways

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Baumeister, Stefan ^a   Wiesner, Jochen ^b   Reichenberg, Armin ^b   Hintz, Martin ^b   Bietz, Sven ^a   Harb, Omar S ^c   Roos, David S ^c   Kordes, Maximilian ^d   Friesen, Johannes ^d   Matuschewski, Kai ^d   Lingelbach, Klaus ^a   Jomaa, Hassan ^b   Seeber, Frank ^a,e  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^e ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 [ACETYL(HYDROXY)AMINO]PROPYLPHOSPHONIC ACID; ANTIPROTOZOAL AGENT; CID 162204; CID 572; FOSMIDOMYCIN; ISOPRENOID; OXIDOREDUCTASE; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; DRUG DERIVATIVE; FOSFOMYCIN;

ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; APICOPLAST; ARTICLE; BABESIA DIVERGENS; BIOSYNTHESIS; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; DRUG MECHANISM; DRUG PENETRATION; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; ENZYME INHIBITION; ERYTHROCYTE MEMBRANE; HOST CELL; HOST PARASITE INTERACTION; HUMAN; HUMAN CELL; ISOTOPE LABELING; NONHUMAN; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; TACHYZOITE; TOXOPLASMA GONDII; ANIMAL; BABESIA; CELL CULTURE; ERYTHROCYTE; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; MOUSE; PARASITOLOGY; PATHOGENICITY; TOXOPLASMA; WESTERN BLOTTING;

APICOMPLEXA; BABESIA; BABESIA DIVERGENS; PLASMODIUM (APICOMPLEXA); PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; TOXOPLASMA GONDII;

ANIMALS; ANTIMALARIALS; BABESIA; BLOTTING, WESTERN; CELLS, CULTURED; ERYTHROCYTES; FLUORESCENT ANTIBODY TECHNIQUE; FOSFOMYCIN; HUMANS; MICE; PLASMODIUM FALCIPARUM; TOXOPLASMA;

EID: 79955781059     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019334     Document Type: Article

References (74)

1. Jomaa H, Wiesner J, Sanderbrand S, Altincicek B, Weidemeyer C, et al. (1999) Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 285: 1573-1576.
2. Cassera M, Gozzo F, D'alexandri F, Merino E, Del Portillo H, et al. (2004) The methylerythritol phosphate pathway is functionally active in all intraerythrocytic stages of Plasmodium falciparum. J Biol Chem 279: 51749-51759.
3. Odom AR, Van Voorhis WC, (2010) Functional genetic analysis of the Plasmodium falciparum deoxyxylulose 5-phosphate reductoisomerase gene. Mol Biochem Parasitol 170: 108-111.
4. Borrmann S, Adegnika AA, Matsiegui PB, Issifou S, Schindler A, et al. (2004) Fosmidomycin-clindamycin for Plasmodium falciparum infections in african children. J Infect Dis 189: 901-908.
5. Borrmann S, Adegnika AA, Moussavou F, Oyakhirome S, Esser G, et al. (2005) Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother 49: 3749-3754.
6. Borrmann S, Lundgren I, Oyakhirome S, Impouma B, Matsiegui PB, et al. (2006) Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria. Antimicrob Agents Chemother 50: 2713-2718.
7. Missinou MA, Borrmann S, Schindler A, Issifou S, Adegnika AA, et al. (2002) Fosmidomycin for malaria. Lancet 360: 1941-1942.
8. Olliaro P, Wells T, (2009) The global portfolio of new antimalarial medicines under development. Clinl Pharmacol Ther 85: 584-595.
9. Kuemmerle HP, Murakawa T, Sakamoto H, Sato N, Konishi T, et al. (1985) Fosmidomycin, a new phosphonic acid antibiotic. Part II: 1. Human pharmacokinetics. 2. Preliminary early phase IIa clinical studies. Int J Clin Pharmacol Ther Toxicol 23: 521-528.
10. Dondorp AM, Yeung S, White L, Nguon C, Day NP, et al. (2010) Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 8: 272-280.
11. Holstein SA, Hohl RJ, (2004) Isoprenoids: remarkable diversity of form and function. Lipids 39: 293-309.
12. Eisenreich W, Bacher A, Arigoni D, Rohdich F, (2004) Biosynthesis of isoprenoids via the non-mevalonate pathway. Cell Mol Life Sci 61: 1401-1426.
13. Seeber F, Soldati-Favre D, (2010) Metabolic pathways in the apicoplast of apicomplexa. Int Rev Cell Mol Biol 281: 161-228.
14. Clastre M, Goubard A, Prel A, Mincheva Z, Viaudmassuart M, et al. (2007) The methylerythritol phosphate pathway for isoprenoid biosynthesis in coccidia: Presence and sensitivity to fosmidomycin. Exp Parasitol 116: 375-384.
15. Lizundia R, Werling D, Langsley G, Ralph SA, (2009) The Theileria apicoplast as a target for chemotherapy. Antimicrob Agents Chemother 53: 1213-1217.
16. Ling Y, Sahota G, Odeh S, Chan JM, Araujo FG, et al. (2005) Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations. J Med Chem 48: 3130-3140.
17. Kirk K, (2001) Membrane transport in the malaria-infected erythrocyte. Physiol Rev 81: 495-537.
18. Cooper B, Chebib M, Shen J, King NJC, Darvey IG, et al. (1998) Structural selectivity and molecular nature of L-glutamate transport in cultured human fibroblasts. Arch Biochem Biophys 353: 356-364.
19. Fouts AE, Boothroyd JC, (2007) Infection with Toxoplasma gondii bradyzoites has a diminished impact on host transcript levels relative to tachyzoite infection. Infect Immun 75: 634-642.
20. Baumeister S, Winterberg M, Duranton C, Huber S, Lang F, et al. (2006) Evidence for the involvement of Plasmodium falciparum proteins in the formation of new permeability pathways in the erythrocyte membrane. Mol Microbiol 60: 493-504.
21. Zintl A, Mulcahy G, Skerrett H, Taylor S, Gray J, (2003) Babesia divergens, a bovine blood parasite of veterinary and zoonotic importance. Clin Microbiol Rev 16: 622-636.
22. Alkhalil A, Hill D, Desai S, (2007) Babesia and plasmodia increase host erythrocyte permeability through distinct mechanisms. Cell Microbiol 9: 851-860.
23. Sivakumar T, Aboulaila M, Khukhuu A, Iseki H, Alhassan A, et al. (2008) In vitro inhibitory effect of fosmidomycin on the asexual growth of Babesia bovis and Babesia bigemina. J Protozool Res 18: 71-78.
24. Tarun AS, Peng X, Dumpit RF, Ogata Y, Silva-Rivera H, et al. (2008) A combined transcriptome and proteome survey of malaria parasite liver stages. Proc Natl Acad Sci USA 105: 305-310.
25. Tsuchiya T, Ishibashi K, Terakawa M, Nishiyama M, Itoh N, et al. (1982) Pharmacokinetics and metabolism of fosmidomycin, a new phosphonic acid, in rats and dogs. Eur J Drug Metab Pharmacokinet 7: 59-64.
26. Murakawa T, Sakamoto H, Fukada S, Konishi T, Nishida M, (1982) Pharmacokinetics of fosmidomycin, a new phosphonic acid antibiotic. Antimicrob Agents Chemother 21: 224-230.
27. Dhiman RK, Schaeffer ML, Bailey AM, Testa CA, Scherman H, et al. (2005) 1-Deoxy-d-xylulose 5-phosphate reductoisomerase (IspC) from Mycobacterium tuberculosis: towards understanding mycobacterial resistance to fosmidomycin. J Bacteriol 187: 8395-8402.
28. Ershov Y, Gantt R, Cunningham FX, Gantt E, (2002) Isoprenoid biosynthesis in Synechocystis sp. strain PCC6803 is stimulated by compounds of the pentose phosphate cycle but not by pyruvate or deoxyxylulose-5-phosphate. J Bacteriol 184: 5045-5051.
29. Woo Y-H, Fernandes RPM, Proteau PJ, (2006) Evaluation of fosmidomycin analogs as inhibitors of the Synechocystis sp. PCC6803 1-deoxy-D-xylulose 5-phosphate reductoisomerase. Bioorg Med Chem 14: 2375-2385.
30. Brown A, Parish T, (2008) Dxr is essential in Mycobacterium tuberculosis and fosmidomycin resistance is due to a lack of uptake. BMC Microbiol 8: 78.
31. Sakamoto Y, Furukawa S, Ogihara H, Yamasaki M, (2003) Fosmidomycin resistance in adenylate cyclase deficient (cya) mutants of Escherichia coli. Biosci Biotechnol Biochem 67: 2030-2033.
32. Sangari FJ, Perez-Gil J, Carretero-Paulet L, Garcia-Lobo JM, Rodriguez-Concepcion M, (2010) A new family of enzymes catalyzing the first committed step of the methylerythritol 4-phosphate (MEP) pathway for isoprenoid biosynthesis in bacteria. Proc Natl Acad Sci USA 107: 14081-14086.
33. Stelter K, El-Sayed NM, Seeber F, (2007) The expression of a plant-type ferredoxin redox system provides molecular evidence for a plastid in the early dinoflagellate Perkinsus marinus. Protist 158: 119-130.
34. Grauvogel C, Reece KS, Brinkmann H, Petersen J, (2007) Plastid isoprenoid metabolism in the oyster parasite Perkinsus marinus connects dinoflagellates and malaria pathogens-new impetus for studying alveolates. J Mol Evol 65: 725-729.
35. Prudencio M, Derbyshire ET, Marques CA, Krishna S, Mota MM, et al. (2009) Plasmodium berghei-infection induces volume-regulated anion channel-like activity in human hepatoma cells. Cell Microbiol 11: 1492-1501.
36. Baumeister S, Winterberg M, Przyborski J, Lingelbach K, (2010) The malaria parasite Plasmodium falciparum: cell biological peculiarities and nutritional consequences. Protoplasma 240: 3-12.
37. Staines HM, Alkhalil A, Allen RJ, De Jonge HR, Derbyshire E, et al. (2007) Electrophysiological studies of malaria parasite-infected erythrocytes: current status. Int J Parasitol 37: 475-482.
38. Stead AMW, Bray PG, Edwards IG, Dekoning HP, Elford BC, et al. (2001) Diamidine compounds: selective uptake and targeting in Plasmodium falciparum. Mol Pharmacol 59: 1298-1306.
39. Biagini GA, Richier E, Bray PG, Calas M, Vial H, et al. (2003) Heme binding contributes to antimalarial activity of bis-quaternary ammoniums. Antimicrob Agents Chemother 47: 2584-2589.
40. Ginsburg H, Stein WD, (1987) New permeability pathways induced by the malarial parasite in the membrane of its host erythrocyte: potential routes for targeting of drugs into infected cells. Biosci Rep 7: 455-463.
41. Staines HM, Ellory JC, Chibale K, (2005) The new permeability pathways: targets and selective routes for the development of new antimalarial agents. Comb Chem High Through Screen 8: 81-88.
42. Gero AM, Dunn CG, Brown DM, Pulenthiran K, Gorovits EL, et al. (2003) New malaria chemotherapy developed by utilization of a unique parasite transport system. Curr Pharm Des 9: 867-877.
43. Hill D, Pillai AD, Nawaz F, Hayton K, Doan L, et al. (2007) A blasticidin S-resistant Plasmodium falciparum mutant with a defective plasmodial surface anion channel. Proc Natl Acad Sci USA 104: 1063-1068.
44. Lisk G, Pain M, Gluzman IY, Kambhampati S, Furuya T, et al. (2008) Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes. Antimicrob Agents Chemother 52: 2346-2354.
45. Dharia NV, Sidhu AB, Cassera MB, Westenberger SJ, Bopp SE, et al. (2009) Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol 10: R21.
46. Staines HM, Rae C, Kirk K, (2000) Increased permeability of the malaria-infected erythrocyte to organic cations. Biochim Biophys Acta 1463: 88-98.
47. Dobson PD, Patel Y, Kell DB, (2009) 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries. Drug Discov Today 14: 31-40.
48. Dobson PD, Kell DB, (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 7: 205-220.
49. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, et al. (2010) Thousands of chemical starting points for antimalarial lead identification. Nature 465: 305-310.
50. Muregi FW, Ishih A, (2010) Next-generation antimalarial drugs: hybrid molecules as a new strategy in drug design. Drug Develop Res 71: 20-32.
51. Deng L, Sundriyal S, Rubio V, Shi Z-z, Song Y, (2009) Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase. J Med Chem 52: 6539-6542.
52. Wiesner J, Ortmann R, Jomaa H, Schlitzer M, (2007) Double ester prodrugs of FR900098 display enhanced in-vitro antimalarial activity. Arch Pharm Chem Life Sci 340: 667-669.
53. Wang W, Li J, Wang K, Huang C, Zhang Y, et al. (2010) Organometallic mechanism of action and inhibition of the 4Fe-4S isoprenoid biosynthesis protein GcpE (IspG). Proc Natl Acad Sci USA 107: 11189-11193.
54. Wang W, Wang K, Liu YL, No JH, Li J, et al. (2010) Bioorganometallic mechanism of action, and inhibition, of IspH. Proc Natl Acad Sci USA 107: 4522-4527.
55. Kamiya T, Hashimoto M, Hemmi K, Takeno H, (1980) Hydroxyaminohydrocarbon-phosphonic acids. 156 US patent 4,206.
56. Öhler E, Kanzler S, (1995) Regioselective palladium(0) catalyzed amination of carbonates of allylic hydroxyphosphonates with hydroxylamine derivatives: A convenient route to phosphonic acids related to the antibiotic fosmidomycin. Synthesis 1995: 539-543.
57. Trager W, Jensen JB, (1976) Human malaria parasites in continuous culture. Science 193: 673-675.
58. Lambros C, Vanderberg JP, (1979) Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol 65: 418-420.
59. Pasvol G, Wilson RJ, Smalley ME, Brown J, (1978) Separation of viable schizont-infected red cells of Plasmodium falciparum from human blood. Ann Trop Med Parasitol 72: 87-88.
60. Seeber F, Boothroyd JC, (1996) Escherichia coli beta-galactosidase as an in vitro and in vivo reporter enzyme and stable transfection marker in the intracellular protozoan parasite Toxoplasma gondii. Gene 169: 39-45.
61. Gorenflot A, Brasseur P, Precigout E, L'Hostis M, Marchand A, et al. (1991) Cytological and immunological responses to Babesia divergens in different hosts: ox, gerbil, man. Parasitol Res 77: 3-12.
62. Giessmann D, Heidler P, Haemers T, Van Calenbergh S, Reichenberg A, et al. (2008) Towards new antimalarial drugs: synthesis of non-hydrolyzable phosphate mimics as feed for a predictive QSAR study on 1-deoxy-D-xylulose-5-phosphate reductoisomerase inhibitors. Chem Biodivers 5: 643-656.
63. Harb OS, Chatterjee B, Fraunholz MJ, Crawford MJ, Nishi M, et al. (2004) Multiple functionally redundant signals mediate targeting to the apicoplast in the apicomplexan parasite Toxoplasma gondii. Eukaryot Cell 3: 663-674.
64. Ralph SA, Van Dooren GG, Waller RF, Crawford MJ, Fraunholz MJ, et al. (2004) Metabolic maps and functions of the Plasmodium falciparum apicoplast. Nat Rev Micro 2: 203-216.
65. Moudy R, Manning TJ, Beckers CJ, (2001) The loss of cytoplasmic potassium upon host cell breakdown triggers egress of Toxoplasma gondii. J Biol Chem 276: 41492-41501.
66. Wiesner J, Hintz M, Altincicek B, Sanderbrand S, Weidemeyer C, et al. (2000) Plasmodium falciparum: Detection of the deoxyxylulose 5-phosphate reductoisomerase activity. Exp Parasitol 96: 182-186.
67. Silvie O, Goetz K, Matuschewski K, (2008) A sporozoite asparagine-rich protein controls initiation of Plasmodium liver stage development. PLoS Pathog 4: e1000086.
68. Janse CJ, Franke-Fayard B, Mair GR, Ramesar J, Thiel C, et al. (2006) High efficiency transfection of Plasmodium berghei facilitates novel selection procedures. Mol Biochem Parasitol 145: 60-70.
69. Friesen J, Silvie O, Putrianti ED, Hafalla JC, Matuschewski K, et al. (2010) Natural immunization against malaria: causal prophylaxis with antibiotics. Sci Transl Med 2: 40ra49.
70. Bruna-Romero O, Hafalla JC, Gonzalez-Aseguinolaza G, Sano G, Tsuji M, et al. (2001) Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. Int J Parasitol 31: 1499-1502.
71. Caspi R, Altman T, Dale JM, Dreher K, Fulcher CA, et al. (2010) The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. Nucleic Acids Res 38: D473-479.
72. Karp PD, Paley S, Romero P, (2002) The Pathway Tools software. Bioinformatics 18 (Suppl 1): S225-232.
73. Henriksson LM, Bjorkelid C, Mowbray SL, Unge T, (2006) The 1.9 A resolution structure of Mycobacterium tuberculosis 1-deoxy-d-xylulose 5-phosphate reductoisomerase, a potential drug target. Acta Crystallogr D Biol Crystallogr D62: 807-813.
74. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25: 1605-1612.